Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Oncopeptides in connection with a directed share issue (2)
Mandate

Vinge advises Oncopeptides in connection with a directed share issue

January 25, 2019

The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncopeptides will raise proceeds of approximately SEK 546 million, before issue costs.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors, on the basis of an accelerated bookbuilding process conducted by Jefferies International Limited, Carnegie Investment Bank AB (publ) and DNB Markets, a part of DNB Bank ASA.

Oncopeptides is a clinical development pharmaceutical company focused on conducting anti cancer research to develop treatments for the benefit of patients. The company’s shares are admitted to trading on Nasdaq Stockholm.

Vinge’s team has consisted of Dain Hård Nevonen, Johan Winnerblad, Rikard Lindahl and Hampus Olsson.

Guidance judgment on the criminal liability for ordering a cabotage transport

The ordering of a road transport made by one of the largest freight forwarders in Sweden has been considered in accordance with the conditions for legal cabotage transports through a decision from the Court of Appeal over Skåne and Blekinge. The Court of Appeal, thus, changes the District Court’s judgment and acquits the freight forwarder. The central issue in the case was how the number of cabotage transports should be calculated.
May 07, 2021

The Scope of Work According to AB 04

 One of the most important parts of a construction agreement is the part where the scope of work is defined. There is a major difference between finding scope of work issues early in a construction project, instead of later during the execution phase.
May 04, 2021

A shift in EU merger control policy and practice could affect deal certainty and create opportunities for complainants

 The European Commission is expanding its control of mergers and acquisitions within the existing legal framework, allowing national authorities to refer a transaction they do not have jurisdiction over for review in Brussels.
April 26, 2021